Xconomy Seattle – [ Updated 3/21/18, 8:42 a.m. EDT. See below.] Alder BioPharmaceuticals is now looking for a new chief executive, just as the company readies plans to file for FDA approval of its lead drug for migraine headaches. Randy Schatzman (pictured above, right) is out as Alder’s (NASDAQ: ALDR) CEO, the Bothell, WA, company announced Tuesday after the markets closed.
Name: Randy Schatzman
Company: Alder BioPharma
Announcement Date: March 19, 2018, 11:00pm
Resignation Date: March 19, 2018, 11:00pm